Inprosub (Progesterone)

Progesterone acts as an agonist at intracellular progesterone receptors. After binding, the hormone‑receptor complex moves into the cell nucleus and regulates the transcription of genes involved in preparing the endometrium for implantation, maintaining pregnancy, and modulating the menstrual cycle. These actions support the hormonal balance required for the therapeutic goals of Inprosub.

The dosage of Inprosub is individualized. A qualified prescriber determines the amount, frequency, and duration of treatment based on the patient’s indication, weight, and clinical response. No standard dosing regimen is provided here; the prescribing information must be consulted for precise guidance.

Progesterone is a natural hormone of pregnancy, and Inprosub may be prescribed when the benefits outweigh potential risks. However, safety data for breastfeeding are limited, and the decision should be made by a healthcare professional after evaluating maternal and infant health. It is not recommended for use without medical supervision in these populations.

To order Inprosub, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide. After the request, the sales team will verify trade or institutional credentials, then provide pricing, availability, shipping details (including cold‑chain logistics if needed), and required import documentation.

Inprosub is a subcutaneous injectable formulation, offering rapid and consistent absorption compared with oral micronized progesterone, which can have variable bioavailability due to first‑pass metabolism. Injectable progesterone provides more reliable serum levels for luteal support and preterm‑birth prevention, while oral forms are often used for chronic hormone replacement but may require higher doses.

Inprosub should be stored at 2‑8 °C (refrigerated). Keep the vials in their original packaging, protect them from light, and avoid freezing or shaking the product. If refrigeration is unavailable for a short period, the product may remain at controlled room temperature for up to 24 hours, but it should be returned to the recommended temperature as soon as possible.

Inprosub is administered by subcutaneous injection, typically into the abdomen or thigh. The injection should be performed by a qualified healthcare professional using aseptic technique. The exact injection site, volume, and frequency are dictated by the prescribing clinician’s instructions and the therapeutic indication.

Serious risks include allergic reactions such as anaphylaxis, thromboembolic events (deep‑vein thrombosis, pulmonary embolism), severe depression or mood disorders, hepatic dysfunction, and severe hypertension. Patients should be monitored closely for signs of these conditions, and therapy should be discontinued immediately if any serious adverse reaction occurs.

Inprosub is contraindicated in individuals with known hypersensitivity to progesterone or any excipients, those with active or uncontrolled thromboembolic disease, severe liver impairment, or unexplained vaginal bleeding. Pregnant or breastfeeding women should only use it under direct medical supervision, and patients with a history of hormone‑sensitive cancers should avoid it unless specifically indicated by a specialist.